Despite recent advances in the treatment of pleural mesothelioma, it remains a challenging and heterogeneous disease, with limited options for patients. Survival rates have only marginally improved in the past years, highlighting the need for a better biological understanding of the disease for the translation into clinical practice. Although recent years have seen substantial progress in genomics and molecular pathology, much of the existing literature has focused on morphology-correlated changes, with molecular, immunohistochemical, clinical, and blood biomarkers largely studied in a correlative framework.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 20 Feb 2026.
The item focuses on Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.
Review the original article for the full source wording and details.